• Explore /
  • Poster
  • / Study EV-103: Update on durability results and long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC).

Study EV-103: Update on durability results and long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC).

Abstract Video & Slides Poster

Authors

null

Terence W. Friedlander

University of California San Francisco Medical Center, San Francisco, CA

Terence W. Friedlander , Matthew I. Milowsky , Mehmet Asim Bilen , Sandy Srinivas , Rana R. McKay , Thomas W. Flaig , Christopher J. Hoimes , Arjun Vasant Balar , Elizabeth Henry , Daniel P. Petrylak , Carolyn Sasse , Ritesh S. Kataria , Yao Yu , Anne-Sophie Carret , Jonathan E. Rosenberg

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Bladder Cancer

Clinical Trial Registration Number

NCT03288545

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 4528)

DOI

10.1200/JCO.2021.39.15_suppl.4528

Abstract #

4528

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Bradley Alexander McGregor

First Author: Nataliya Mar

First Author: Jonathan E. Rosenberg

First Author: Christopher J. Hoimes